2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Abstract Full Text (PDF) All Versions of this Article: ASN.2005101095v1 17/9/2554    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miller, J. A. Articles by Scholey, J. W. Search for Related Content PubMed PubMed Citation Articles by Miller, J. A. Articles by Scholey, J. W. Related Collections Related Article

Gender Differences in the Renal Response to Renin-Angiotensin System Blockade

Department of Medicine, University of Toronto, Toronto, Ontario, Canada

Address correspondence to: Dr. Judith A. Miller, Toronto General Hospital, 8N-846, 585 University Avenue, Toronto, Ontario, M5G 2N2. Phone: 416-340-4966; Fax: 416-340-4951; E-mail: judith.miller{at}utoronto.ca

Received for publication October 21, 2005. Accepted for publication June 25, 2006.

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion Conclusion References

 
Evidence suggests that gender differences exist in renin-angiotensin system (RAS) function. It was hypothesized that women may differ also in their response to RAS blockade. The renal and peripheral hemodynamic responses to incremental dosages of an angiotensin receptor blocker and the degree of angiotensin II (AngII) insensitivity achieved during 8 wk were examined in men and women. Participants were 30 young healthy men (n = 15; mean age 27 ± 2) and women (n = 15; mean age 28 ± 2) who were on a controlled sodium and protein diet for 1 wk before each study. The humoral, renal, and systemic response to incremental dosages of irbesartan (75 mg for 4 wk, then 150 mg for 4 wk) was assessed, as was the pressor response to AngII (3 ng/kg per min), at 2-wk intervals. AngII type 1 receptor expression in skin biopsies was assessed at baseline and after 8 wk by a real-time PCR protocol. Men and women both exhibited significant declines in BP. Women achieved significantly reduced AngII sensitivity compared with men at lower dosages, showing no pressor response at 4 wk of 75 mg/d irbesartan, whereas men continued to exhibit a pressor response at 4 wk of 150 mg/d. Receptor expression at baseline did not differ between men and women but by 8 wk was significantly decreased in women and unchanged in men. Our findings indicate that men may require larger dosages of angiotensin receptor blocker than do women and that the BP response cannot be used as a surrogate marker for adequate RAS blockade of the renal microvasculature.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion Conclusion References

 
Clinical and epidemiologic evidence suggests that women with renal disease progress more slowly to end stage in comparison with men (1). The mechanisms underlying this difference remain unknown, but evidence indicates that at least one explanation for this phenomenon is a physiologic gender-based difference in the function of the renin-angiotensin system (RAS). This system is an important mediator of renal and cardiovascular physiology and pathophysiology (2,3), and angiotensin II (AngII) is its principal effector. Studies from our laboratory have demonstrated distinct gender differences in RAS function (4–7). In vivo findings in the canine have shown that estrogen replacement after ovariectomy reduces AngII type 1 (AT₁) receptor number in several tissues, including kidney (8). Studies in mouse models of vascular disease have suggested that estrogen and AngII receptor blockers (ARB) act synergistically on several outcomes, including atherosclerotic changes (9) and neointimal thickening after vascular injury (10).

Taken together, these experiments in the animal and human models suggest a possible synergistic effect between ARB and estrogen. We therefore examined AT₁ receptor blockade by ARB in young, healthy men and women. It was hypothesized that such a synergistic effect would manifest in gender differences in the extent to which ARB administration results in decreased AngII sensitivity and reduced receptor expression (11,12). These experiments were conducted in young, healthy individuals who were on a controlled sodium and protein diet. Renal hemodynamic function was assessed using classic inulin and para-aminohippurate (PAH) clearance techniques. The extent of AT₁ receptor blockade was assessed by three independent means: The response to an AngII challenge during treatment with irbesartan, an ARB that is used commonly in clinical practice; reactive changes in circulating levels of renin and AngII with irbesartan treatment; and the change in tissue AT₁ receptor expression gleaned from skin biopsy tissue (13). Identical dosages were used in both men and women because these medications are not marketed as requiring dosage adjustment on the basis of body size or gender. The study was conducted during an 8-wk period, during which each participant was studied on five occasions.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion Conclusion References

 
Thirty normal, healthy men and women were recruited to participate in this study (15 men and 15 women). Their mean age was 27 ± 2 yr. Each participant underwent a detailed history and physical examination by a qualified internist. All were normotensive, nonobese, and nonsmokers. No participant was ingesting any regular medications, including oral contraceptives. The study was performed with the approval of the University Health Network Research Ethics Board and with the informed written consent of each participant.

All participants were counseled to adhere to a diet that maintained their normal caloric intake, their sodium intake to >2 mmol/kg per 24 h, and their protein intake to 1 to 1.5 g/kg per 24 h for 7 d before each phase of the study. A 24-h urine sample was collected to determine compliance with the diet, and data from participants were used only when the excretion rate of sodium was >2 mmol/kg per d and the urea excretion rate was between 3 and 6 mmol/kg per d. No data were excluded on this basis. Protein intake was estimated from the urine urea concentration using standard equations and was corrected for body weight. The participants were advised not to ingest any caffeine for 12 h before the study. On each day of the testing, the participants reported to the Renal Physiology Laboratory at the Toronto General Hospital. All studies were conducted at 8:30 a.m. with the participants lying supine in a warm, quiet room.

Study Protocol
On each study day, an 18-G peripheral venous cannula was inserted into an antecubital vein for infusions of inulin, PAH, and AngII, and another cannula was placed in the opposite arm for blood sampling. Each participant voided spontaneously before starting the study. Hemodynamic parameters (mean arterial pressure [MAP] and heart rate) were measured throughout the study by an automated sphygmomanometer (Dinamap, Criticon, Tampa, FL) and were recorded once in each half hour of the protocol. Renal hemodynamic function was measured using inulin and PAH clearance techniques. After collection of blood for inulin and PAH blank, hematocrit (HCT), 17-estradiol (in women only), plasma renin concentration (PRC), and plasma AngII, a priming infusion that contained 25% inulin (60 mg/kg) and 20% PAH (8 mg/kg) was administered. Thereafter, inulin and PAH were infused continuously at a rate that was calculated to maintain their respective plasma concentrations constant at 20 and 1.5 mg/dl. Participants remained supine at all times. After a 90-min equilibration period and in each half hour for 90 min, blood was collected for inulin, PAH, and HCT. GFR and effective renal plasma flow (ERPF) were estimated by steady-state infusion of inulin and PAH according to the calculation method described by Schnurr et al. (14).

A solution of AngII (51.2 µg/vial; Clinalfa, Läufelfingen, Switzerland) was prepared by dissolving the diluent in 1 ml of normal saline to produce a concentration of 50 µg/ml. A total of 99 ml of normal saline then was added to 1 ml of AngII to produce a concentration of 500 ng/ml. AngII was infused at 3 ng/kg per min for 30 min. Participants remained supine. Blood was collected once at the end of the AngII infusion period for HCT, inulin, and PAH. An additional collection of blood for HCT, inulin, and PAH was obtained at the end of a 30-min recovery period.

Participants then were initiated on irbesartan, 75 mg once daily for a total of 4 wk. The experiments were repeated after 2 and 4 wk on this dosage. They then were initiated on irbesartan 150 mg once daily for a total of 4 wk. They were studied similarly at 2 and 4 wk on the increased dosage. In women, the baseline AngII infusion was administered during the luteal (high estrogen) phase of the menstrual cycle. Skin biopsies were obtained from 10 participants in each group on the first study day and on the last study day, under sterile conditions, after subcutaneous installation of local anesthetic with Xylocaine, as described previously (6).

Sample Collection and Analytic Methods
Blood samples that were collected for inulin and PAH determinations were centrifuged immediately at 3000 rpm for 15 min at 4°C. Plasma was separated, placed on ice, and then stored at –70°C before the assay. Inulin concentrations were measured by a modified method of Walser et al. (15), and PAH concentration was measured by a spectrophotometric method according to Brun (16). The mean of the two pre-AngII clearance periods represented baseline GFR and ERPF, expressed per 1.73 m². Filtration fraction (FF) represented the ratio of GFR to ERPF. Renal blood flow (RBF) was calculated by dividing the ERPF by (1 – HCT). Renal vascular resistance (RVR) was derived by dividing MAP by the RBF.

AngII was measured by RIA. Blood was collected into prechilled tubes that contained EDTA and angiotensinase inhibitor (0.1 ml of Bestatin Solution; Buhlmann Laboratories, Schonembuch, Switzerland). After centrifugation, plasma samples were stored at –70°C until analysis. On the day of analysis, plasma samples were extracted on phenylsilylsilica columns. A competitive RIA kit supplied by Buhlmann Laboratories was used to measure the extracted AngII. The detection limit of the assay was approximately 2.0 pg/ml, with a precision of 8.3% intra-assay variation and 9.0% interassay variation.

PRC was measured by two-site immunoradiometric assay in which two mAb to human active renin are used. One antibody was coupled to biotin, and the second was radiolabeled for detection. The sample that contained active renin was incubated simultaneously with both antibodies to form a complex. The radioactivity of this complex was directly proportional to the amount of immunoreactive renin present in the sample (17). Plasma 17-estradiol was determined by RIA using the DPC kit (Drug Products Corp., Los Angeles, CA).

Skin biopsies were stored in liquid nitrogen at –70°C before processing. AT₁ mRNA levels were assessed by a PCR protocol. RNA was isolated using an RNeasy kit (Qiagen, Mississauga, ON, Canada), and 25 to 50 ng was used per reaction. Reverse transcriptase–PCR was performed using a One-Step RT-PCR kit (Applied Biosystems, Foster City, CA). One-step PCR was performed under the following conditions: 48°C for 30 min and 95°C for 10 min, followed by 45 cycles of 95°C for 15 s and 60°C for 60 s, using a real-time PCR protocol, the ABI PRISM 7000 Sequence Detection System. The human AT₁ receptor forward primer was 5'-AAATGGCTGGGTTTTTATCTGAAT-3', and the reverse primer was 5'-TTTTGATCACCTGGGTCGAATT-3', corresponding to bp 67 to 90 and 152 to 173 of the human AT₁ receptor cDNA sequence, respectively. The final concentration of AT₁ primers was 0.5 µM. The human AT₁ probe was 5'-ACTCACTGATGCCATCCCAGAAAGTCG-3', corresponding to bp 92 to 119 of the human cDNA sequence. The AT₁ receptor probe used a FAM dye with a TAMRA quencher at a final concentration of 0.2 µM. For internal control, human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers were used, supplied by the manufacturer (TaqMan GAPDH Control reagents; Applied Biosystems), at a final concentration of 0.1 µM. The final concentration of human GAPDH probe was 0.05 µM. The GAPDH probe used a JOE dye and a TAMRA quencher, as per the manufacturer. Standard curves were developed with RNA that was obtained from human kidney cortex (0.4 to 50 ng). Experiments were performed in duplicate or triplicate and repeated at least once. Data are presented as the ratio of human AT₁ receptor mRNA/GAPDH mRNA, in arbitrary units (6).

Statistical Analyses
Results are presented as mean ± SE. Between-group baseline differences were determined using nonparametric methods (Wilcoxon rank sums). Within-subject and between-group differences in the longitudinal responses to irbesartan and the acute responses to AngII infusion were determined by repeated measures ANOVA and Bonferroni correction. Within-subject and between-group differences in AT₁ receptor expression were assessed using nonparametric methods. All statistical analyses were performed using the statistical package SAS (SAS Institute Inc., Cary, NC). P 0.05 was designated to represent statistical significance.

	Results

Top Abstract Introduction Materials and Methods Results Discussion Conclusion References

 
Baseline Parameters
Participants were similar in age, body mass index (BMI), urine sodium excretion, protein intake per kilogram per day, plasma AngII, and PRC (Table 1). A baseline significant difference was detected in body surface area (BSA), weight (Table 1), MAP, and RVR (Table 2).

During the course of the study, MAP (Figure 1) and RVR declined significantly in men and women with no significant gender differences in the responses. There were no significant changes detected in GFR, ERPF, RBF, or FF over time (Table 2).

View larger version (14K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 1. Mean arterial pressure at baseline and in response to incremental angiotensin II (AngII) receptor blockers (ARB) in men and women at 75 mg at 2 and 4 wk and at 150 mg at 2 and 4 wk. *P < 0.05 versus baseline.

View larger version (15K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 2. Plasma renin concentration at baseline and in response to incremental ARB in men and women at 75 mg at 2 and 4 wk and at 150 mg at 2 and 4 wk. *P < 0.05 versus baseline; #P < 0.05 versus response in men.

View larger version (15K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 3. Plasma AngII at baseline and in response to incremental ARB in men and women at 75 mg at 2 and 4 wk and at 150 mg at 2 and 4 wk. *P < 0.05 versus baseline; #P < 0.05 versus response in men.

View larger version (19K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 4. AngII type 1 (AT1) receptor mRNA expression at baseline and after 8 wk of irbesartan in men and women. *P < 0.05 versus baseline.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion Conclusion References

Our major finding was that the response to AngII infusion was abolished in women at low dosages of irbesartan after 4 wk, whereas AngII insensitivity never was achieved in men, even after 4 wk of 150 mg. Similarly, in women, renin and AngII plasma levels were elevated maximally by 4 wk of low-dosage irbesartan, whereas in men, levels approached those in women only at 4 wk of 150 mg/d irbesartan. Furthermore, AT₁ receptor mRNA expression showed no gender difference at baseline, but after 8 wk of irbesartan therapy, expression levels were significantly decreased in women but unchanged in men (Figure 4).

Reasons for this gender difference in susceptibility to AT₁ receptor blockade are not readily obvious from this protocol. It seems unlikely that this phenomenon could have occurred by chance, given the degree of significance achieved and the parallel results provided by the three independent methods that were used to assess blockade. Lack of compliance in men also seems unlikely because the longitudinal MAP response was appropriate in both men and women, and circulating RAS components did eventually rise in men, although only at larger dosages. The gender difference cannot be attributed to variations in sodium or protein intake, because these parameters were similar in men and women after correction for body weight. It is evident that women received higher dosages than did men when corrected for BSA and weight but not BMI. However, further examination reveals that AngII insensitivity was achieved in women at dosages that were significantly lower than those required by men, when factored by BSA and weight, suggesting that body size alone cannot explain the results. It is important to reiterate that these medications are not marketed to be dosed by body weight, BSA, or BMI.

Sex hormones may explain this phenomenon (24). Studies in animal models have demonstrated that estrogen and RAS blockade may act synergistically to downregulate the AT₁ receptor. In a set of experiments in a polyethylene cuff–induced vascular injury mouse model, Liu et al. (10) studied male, female intact, and female ovariectomized mice that were treated with estrogen alone, olmesartan alone, and estrogen and olmesartan in combination. Neointimal thickening was significantly less in intact female than in male mice, differences that were abolished by ovariectomy. Low-dosage olmesartan inhibited neointimal thickening only in female mice. Co-administration of estrogen and olmesartan to ovariectomized mice synergistically inhibited neointima formation and DNA synthesis. Similar results were obtained by Tsuda et al. (9) in ovariectomized mice that were fed a high-cholesterol diet, wherein co-administration of estrogen and olmesartan improved atherosclerosis without changing plasma cholesterol levels. This gender difference also seems to be relevant to humans who receive ACE inhibition. In the Ramipril Efficacy in Nephropathy (REIN) study, the investigators noted a significantly augmented renal survival and antiproteinuric impact of ramipril in women compared with men (18).

The AT₁ receptor expression results deserve comment. It has been shown in experimental models that ARB therapy can reduce AT₁ receptor mRNA expression (11,12). The mechanism in unclear but could be due to ARB-mediated increases in circulating AngII augmenting the formation of Ang 1 to 7 (25) or activating AT₂ receptors (26). Although this study cannot clarify the mechanism, it is clear that, similar to other measures of adequacy of RAS blockade, women exhibited an augmented response. It is plausible that RAS blockade and estrogen acted synergistically to decrease mRNA receptor expression. In an in vivo study by Owonikoko et al. (8) in an ovariectomized canine model, the effect of estrogen on AT₁ receptor expression was assessed with noninvasive positron emission tomography imaging techniques. This revealed that estrogen replacement after ovariectomy resulted in decreased AT₁ receptor ligand binding in the renal cortex and the adrenal gland compared with the estrogen-depleted state. Therefore, estrogen alone may have affected AT₁ receptor expression; however, this is unlikely because at the time of both skin biopsies, women were in the luteal phase, and estrogen levels did not differ. In this set of experiments, the AT₁ receptor expression results correlate well with the physiologic responses, as in a previous study from this laboratory (6). Taken together, these two observations suggest that AT₁ receptor mRNA levels are associated with responsiveness to AngII and AngII blockade.

Another finding from our study deserves comment. Previous studies (27,28) revealed that there were no clinically significant differences in irbesartan pharmacokinetics between men and women, and, indeed, during the course of the study, the irbesartan-mediated reduction in MAP was similar in both groups. However, the striking differences in AngII sensitivity between ARB-treated men and women indicate that the MAP response to ARB cannot be used as an indication of blockade of the renal microvasculature. The mechanism for the further decline in BP values cannot be determined from this protocol but may relate to the ongoing natriuretic effect of ARB therapy, resulting in a negative sodium balance.

This study has several limitations. First, the study sample was not from a target patient population in that participants were selected for normal arterial pressure, renal function, and urinalysis. By studying a healthy sample, we hoped to examine the impact of gender, without confounding factors. Because this study provides physiologic evidence for gender differences in the response to RAS blockade, it could serve as a starting point for a similar study in patients with renal disease. A second limitation was the study length. Although evidence exists to suggest that ARB achieve blood levels rapidly and exert their antiproteinuric and vasodilatory effects within the time frame of this study (29), it is possible that further blockade of the RAS would have occurred if the study duration were longer. A third limitation was the dosage of irbesartan used. In a study by Ribstein et al. (30), the systolic BP response to AngII infusion was assessed before and after treatment with varying dosages of irbesartan. The authors found that the pressor response was blocked completely at peak drug levels with dosages of 150 and 300 mg and that the pressor inhibitory effect of irbesartan was dosage dependent. This suggests that if higher dosages had been used in the men in our study, then full blockade may have been achieved. Importantly, enrollment in the Ribstein study was restricted to normotensive, lean, white men who were between 18 and 35 yr of age. The possibility that women may require smaller dosages to achieve full blockade was not addressed. Last, the sample size of the study was small as a result of the practical difficulties of recruiting and studying healthy individuals in such a detailed and complex manner. We attempted to minimize the effect of the small sample size by having homogeneous study groups. We ensured that participants were ingesting similar amounts of salt and protein to minimize RAS activation, that no female participant was ingesting oral contraceptive medications, and that all female participants were studied in the same phase of the menstrual cycle at each point in the protocol. Perhaps because of this careful prestudy preparation, the sample size was large enough to show significant findings that are biologically plausible and in keeping with previous animal and human data.

	Conclusion

Top Abstract Introduction Materials and Methods Results Discussion Conclusion References

 
Normotensive men and women with normal renal function respond differently to RAS blockade with irbesartan, at the level of both the peripheral vasculature and the renal microvasculature. Our findings also indicate that men may require larger dosages of ARB than do women and that the BP response cannot be used as a surrogate marker for adequate RAS blockade of the renal microvasculature. Although mechanisms that are responsible for the protective effect of female gender on progression of renal disease were not addressed, increased sensitivity to modulation of the RAS as observed in these studies could account in part for the different rates of progression in women.

	Acknowledgments

 
This work was supported by a New Emerging Team grant from the Canadian Institutes of Health Research (to J.A.M., D.C.C., and J.W.S.) and grants from the Physicians’ Services Foundation Inc. (to J.A.M. and D.C.C.) and the Heart and Stroke Foundation of Canada (to J.A.M.; grant NA 5008). D.Z.C. received funding from the KRESCENT program and the University of Toronto Clinician Scientist Program.

We acknowledge Clinalfa for providing AngII and PAH for these experiments.

	Footnotes

 
Published online ahead of print. Publication date available at www.jasn.org.

This paper, describing an association of birth weight with blood pressure at age 7 yr in black but not white children, adds to understanding the complex interactions between race and renal disease that are also illustrated by the paper by Newsome et al. in the accompanying issue of CJASN, which describes racial differences in survival after acute myocardial infarct that favor blacks over whites with more severe degrees of renal insufficiency (Newsome et al., pages 993–999).

 

	References

Top Abstract Introduction Materials and Methods Results Discussion Conclusion References

 

1. Silbiger SR, Neugarten J: The role of gender in the progression of renal disease. Adv Ren Replace Ther 10 : 3–14, 2003[CrossRef][Medline]
2. Fakhouri F, Placier S, Ardaillou R, Fakhouri F, Placier S, Ardaillou R, Dussaule JC, Chatziantoniou C: Angiotensin II activates collagen type 1 gene in the renal cortex and aorta of transgenic mice through interaction with endothelin and TGF-beta. J Am Soc Nephrol 12 : 2701–2710, 2001[Abstract/Free Full Text]
3. Hall JE, Brands MW, Henegar JR: Angiotensin II and long-term arterial pressure regulation: The overriding dominance of the kidney. J Am Soc Nephrol 10[Suppl 12] : S258–S265, 1999
4. Miller JA, Anacta L, Cattran DC: Impact of gender on the renal response to angiotensin II. Kidney Int 55 : 278–285, 1999[CrossRef][Medline]
5. Kang AK, Duncan JA, Cattran DC, Floras JS, Lai V, Scholey JW, Miller JA: Effect of oral contraceptives on the renin angiotensin system and renal function. Am J Physiol 280 : R807–R813, 2001
6. Ahmed SB, Kang AK, Burns KD, Kennedy CRJ, Lai V, Cattran DC, Scholey JW, Miller JA: Effects of oral contraceptive use on the renal and systemic vascular response to angiotensin II infusion. J Am Soc Nephrol 15 : 780–786, 2004[Abstract/Free Full Text]
7. Chidambaram M, Duncan JA, Lai VS, Cattran DC, Floras JS, Scholey JW, Miller JA: Variations in the renin angiotensin system throughout the normal menstrual cycle. J Am Soc Nephrol 13 : 446–452, 2002[Abstract/Free Full Text]
8. Owonikoko TF, Fabucci ME, Brown PR, Nisar N, Hilton J, Mathews WB, Ravert HT, Rauseo P, Sandberg K, Dannals RF, Szabo Z: In vivo investigation of estrogen regulation of adrenal and renal angiotensin (AT1) receptor expression by PET. J Nucl Med 45 : 94–100, 2004[Abstract/Free Full Text]
9. Tsuda M, Iwai M, Li JM, Li HS, Min LJ, Ide A, Okumura M, Suzuki J, Mogi M, Suzuki H, Horiuchi M: Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension 45 : 545–551, 2005[Abstract/Free Full Text]
10. Liu H-W, Iwai M, Takeda-Matsubara Y, Wu L, Li J-M, Okumura M, Cui T-X, Horiuchi M: Effect of estrogen and AT1 receptor blocker on neointima formation. Hypertension 40 : 450–457, 2002
11. Haddad G, Amiri F, Garcia R: Modulation of renal glomerular angiotensin II receptors by ace inhibition and AT1 receptor antagonism. Regul Pept 68 : 111–117, 1997[CrossRef][Medline]
12. Makino N, Sugano M, Otsuka S, Hata T: Molecular mechanism of angiotensin II type 1 and type 2 receptors in cardiac hypertrophy of spontaneously hypertensive rats. Hypertension 30 : 796–802, 1997[Abstract/Free Full Text]
13. Nickenig G, Geisen G, Vetter H, Sachinidis A: Characterization of angiotensin receptors on human skin fibroblasts. J Mol Med 75 : 217–222, 1997[CrossRef][Medline]
14. Schnurr E, Lahme W, Kuppers H: Measurement of renal clearance of inulin and PAH in the steady state without urine collection. Clin Nephrol 13 : 26–29, 1980[Medline]
15. Walser M, Davidson DG, Orloff J: The renal clearance of alkali-stable inulin. J Clin Invest 34 : 1520–1523, 1955[Medline]
16. Brun C: A rapid method for the determination of para-aminohippuric acid in kidney function tests. J Clin Lab Med 37 : 955–958, 1951[Medline]
17. Simon D, Hartmann DJ, Badouaille G, Caillot G, Guyenne TT, Corvol P, Pau B, Marchand J: Two-site direct immunoassay specific for active renin. Clin Chem 38 : 1959–1962, 1992[Abstract]
18. Ruggenenti P, Perna A, Zoccali C, Gherardi G, Bennini R, Testa A, Remuzzi G: Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: Differences between women and men in relation to the ACE gene polymorphism. J Am Soc Nephrol 11 : 88–96, 2000[Abstract/Free Full Text]
19. Delacrétaz E, Nussberger J, Biollaz J, Waeber B, Brunner HR: Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 25 : 14–21, 1995[Abstract/Free Full Text]
20. Munafo A, Christen Y, Nussberger J, Shum LY, Borland RM, Lee RJ, Waeber B, Biollaz J, Brunner HR: Drug concentration response relationships in normal volunteers after oral administration of losartan, and angiotensin II receptor antagonist. Clin Pharmacol Ther 51 : 513–521, 1992[Medline]
21. Hagmann N, Nussberger J, Naudin RB, Burns TS, Karim A, Waeber B, Brunner HR: SC-52458, an orally active angiotensin II-receptor antagonist: Inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers. J Cardiovasc Pharmacol 29 : 444–450, 1997[CrossRef][Medline]
22. Püchler K, Nussberger J, Laeis P, Witte PU, Bruneer HR: Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients. J Hypertens 15 : 1809–1812, 1997[CrossRef][Medline]
23. Hubner R, Hogemann AM, Sunzel M, Riddell JG: Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 11 : S19–25, 1997
24. Silbiger SR, Neugarten J: The impact of gender on the progression of chronic renal disease. Am J Kidney Dis 4 : 515–533, 1995
25. Clark MA, Tallant A, Bosch S, Diz D: Angiotensin-(1-7) reduces renal angiotensin II receptors through a cyclooxygenase-dependent mechanism. J Cardiovasc Pharmacol 41 : 276–283, 2003[CrossRef][Medline]
26. Tanaka M, Tsuchida S, Imai T, Nobuharu F, Miyazaki H, Ichiki T, Naruse M, Inagami T: Vascular response to angiotensin II is exaggerated through an upregulation of AT1 receptor in AT2 receptor knockout mice. Biochem Biophys Res Commun 258 : 194–199, 1999[CrossRef][Medline]
27. Vachharajani NN, Shyu WC, Smith RA, Greene DS: The effects of age and gender on the pharmacokinetics of irbesartan. Br J Clin Pharmacol 46 : 611–613, 1998[CrossRef][Medline]
28. Marino MR, Vachharajani NN: Pharmacokinetics of irbesartan are not altered in special populations. J Cardiovasc Pharmacol 40 : 112–122, 2002[CrossRef][Medline]
29. Maillard MP, Würzner G, Nussberger J, Centeno C, Burnier M, Brunner HR: Comparative angiotensin II receptor blockade in healthy volunteers: The importance of dosing. Clin Pharmacol Ther 71 : 68–76, 2002[CrossRef][Medline]
30. Ribstein J, Picard A, Armagnac C, Sissmann J, Mimran A: Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men. J Cardiovasc Pharmacol 37 : 449–460, 2001[CrossRef][Medline]

This article has been cited by other articles:

				D. Z. I. Cherney, J. W. Scholey, R. Nasrallah, M. G. Dekker, C. Slorach, T. J. Bradley, R. L. Hebert, E. B. Sochett, and J. A. Miller Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus Am J Physiol Renal Physiol, June 1, 2008; 294(6): F1336 - F1341. [Abstract] [Full Text] [PDF]

				D. H. T. IJpelaar, A. Schulz, K. Koop, M. Schlesener, J. A. Bruijn, D. Kerjaschki, R. Kreutz, and E. de Heer Glomerular hypertrophy precedes albuminuria and segmental loss of podoplanin in podocytes in Munich-Wistar-Fromter rats Am J Physiol Renal Physiol, April 1, 2008; 294(4): F758 - F767. [Abstract] [Full Text] [PDF]

				J. C. Sullivan Sex and the renin-angiotensin system: inequality between the sexes in response to RAS stimulation and inhibition Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2008; 294(4): R1220 - R1226. [Abstract] [Full Text] [PDF]

				J. C. Sartori-Valinotti, R. Iliescu, L. L. Yanes, W. Dorsett-Martin, and J. F. Reckelhoff Sex Differences in the Pressor Response to Angiotensin II When the Endogenous Renin-Angiotensin System Is Blocked Hypertension, April 1, 2008; 51(4): 1170 - 1176. [Abstract] [Full Text] [PDF]

				J. C. Sullivan, L. Semprun-Prieto, E. I. Boesen, D. M. Pollock, and J. S. Pollock Sex and sex hormones influence the development of albuminuria and renal macrophage infiltration in spontaneously hypertensive rats Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1573 - R1579. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: ASN.2005101095v1 17/9/2554    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miller, J. A. Articles by Scholey, J. W. Search for Related Content PubMed PubMed Citation Articles by Miller, J. A. Articles by Scholey, J. W. Related Collections Related Article